Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) (RELAZA2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01462578
Recruitment Status : Active, not recruiting
First Posted : October 31, 2011
Last Update Posted : December 10, 2018
Information provided by (Responsible Party):
Technische Universität Dresden